RedHill Biopharma reported $26.27M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 138.36M 7.5M Jun/2026
Cronos Group USD 1.2B 18.15M Sep/2026
RedHill Biopharma USD 26.27M 929K Jun/2026